Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2023-11-02 00:00:00 ET · period of report 2023-10-31 · accession 0001415889-23-014714 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-11-02 | 2023-10-31+ | OLMA | Harmon Cyrus | Dir | S - Sale | $12.65 | -30.0K | 943.7K | -3% | -$379.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-31 | S | D | 25,000 | $12.05 | 948,714 | D | — | — | (F2) The weighted average sale price for the transaction reported was $12.05, and the range of prices were between $11.19 and $13.24. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2023-11-02 | S | D | 5,000 | $15.64 | 943,714 | D | — | — | (F3) The weighted average sale price for the transaction reported was $15.64, and the range of prices were between $15.55 and $15.75. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |